Healthcare / BiotechnologyNasdaqCM
$9.07
-0.24 (-2.58%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-35.4M · quality 70.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-37.9%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-26.9M · FCF $-28.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | — | — | — | — | $1.0M | $7.6M | $1.9M | $0.00 | — | — | — | — | $9.3M | $2.5M | $0.00 | $0.00 | — |
| Net Income | $-26.9M | $-26.9M | $-30.9M | $-37.3M | $-41.3M | $-20.7M | $-16.8M | $-19.3M | $-27.7M | $-23.8M | $-17.7M | $-63.9M | $-36.6M | $-76.7M | $-35.0M | $-11.5M | $-12.0M |
| EBITDA | $-28.3M | $-28.3M | $-31.5M | $-37.9M | $-31.9M | — | — | — | — | — | $-16.0M | $-34.1M | $-43.8M | $-28.2M | $-21.1M | $-12.3M | — |
| EPS | -0.25 | -0.25 | -0.50 | -1.34 | -2.13 | -1.34 | -2.11 | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | 90.0% | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | -3195.0% | -332.8% | -893.8% | — | — | — | — | — | -471.1% | -1145.5% | — | — | — |
| Net Margin | — | — | — | — | -4130.1% | -272.4% | -881.9% | — | — | — | — | — | -392.8% | -3083.2% | — | — | — |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 0.01 | 0.01 | 0.11 | -0.11 | 0.19 | — | — | — | 0.00 | 1.26 | — | 0.00 | 0.12 | 1.32 | 0.00 | — | — |
| Current Ratio | 17.22 | 17.22 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-28.4M | $-28.4M | $-35.4M | $-36.9M | $-28.3M | — | — | — | — | — | $-11.9M | $-48.3M | $-42.9M | $-29.2M | $-21.7M | $-14.7M | $-10.4M |
| Returns | |||||||||||||||||
| ROE | -37.9% | -37.9% | -326.3% | 468.2% | -851.4% | -101.7% | -59.9% | -316.6% | -527.6% | -1147.5% | 353.8% | 521.1% | -98.8% | -1302.7% | -126.0% | -113.6% | -493.5% |
| Valuation | |||||||||||||||||
| P/B | 13.96 | 13.96 | 6.98 | — | 10.80 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | — | — | — | — | — | 300.0% | — | — | — | — | — | — | 274.7% | — | — | — | — |
| EPS Growth | 50.0% | 50.0% | 62.7% | 37.1% | — | 36.5% | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+430.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.50 → -0.25
Residual
+430.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.